Dr. Eman Mamdoh, Assistant Lecturer in the Department of Pharmacognosy at the Faculty of Pharmacy, Horus University, delivered a comprehensive presentation on the research findings related to Gardenia thunbergia Thunb. leaves. Her talk focused on two key studies: the elucidation of natural components of Gardenia thunbergia Thunb. leaves, particularly the effect of methanol extract and rutin on non-alcoholic fatty liver disease (NAFLD), and the GC-MS analysis of the bioactive compounds in these leaves, emphasizing their antibiofilm potential against Staphylococcus aureus clinical isolates.

Dr. Eman explained that the first study explored the therapeutic potential of Gardenia thunbergia Thunb. in treating NAFLD, a condition characterized by excessive fat accumulation in the liver unrelated to alcohol consumption. Through the use of Gas Chromatography-Mass Spectrometry (GC-MS), the study identified several bioactive compounds in the leaves. The biological evaluation demonstrated that both the methanol extract and rutin significantly reduced liver fat accumulation and improved liver function in animal models, suggesting a protective role against NAFLD.

In the second study, Dr. Eman highlighted the antimicrobial potential of these bioactive compounds, particularly their ability to inhibit biofilm formation by Staphylococcus aureus, a major pathogen known for its resistance to many antibiotics due to its biofilm-forming ability. The GC-MS analysis revealed compounds that were effective in preventing biofilm formation, indicating their potential as alternative antimicrobial agents.

Dr. Eman concluded by emphasizing the importance of these findings in the broader context of natural product research. The studies not only underscore the potential of Gardenia thunbergia Thunb. as a source of therapeutic agents for liver diseases but also its role in addressing antibiotic resistance issues through its antibiofilm properties. Her presentation highlighted the promising future of integrating natural compounds into clinical treatments, pending further research and clinical trials.